The story of the erectile dysfunction drug presents a complex picture for investors. While the initial launch generated substantial profits, the expiration of its exclusive rights opened the floodgates to off-brand https://rajanjato020932.verybigblog.com/40586938/sildenafil-and-the-pharmaceutical-industry-a-precarious-investment